Drug Trial Radar · NCT07104799
Momelotinib During and After HCT in Myelofibrosis
Last checked: Nov 20, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
28
Planned (sponsor's estimate)
Start
Feb 23, 2026
Primary completion
Jan 2028
Study completion Jan 2030
Sponsor
- Lead sponsor
- Massachusetts General HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- GlaxoSmithKline
- First posted
- Aug 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-center, open-label, phase I study to determine the safety and tolerability of momelotinib in patients with myelofibrosis during and after hematopoietic cell transplantation (HCT).
Conditions
- Myelofibrosis
- Hematopoietic Cell Transplantation (HCT)
Interventions
MomelotinibDrug
Administered orally once per day during each 28-day cycle. This will start on day -7 (7 days before HCT) and continue for up to 13 cycles. Dose cohorts (100 mg daily, 150 mg daily, 200 mg daily) will be investigated in the peri-transplant period. Once participants have achieved hematopoietic recovery and are at least Day 21 after HCT, participants will increase the dose to 200 mg daily.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Maximum Tolerated Dose (MTD) of MomelotinibTime frame: From start of study treatment (Day -7) through 28 days.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Massachusetts General Hospital
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.